ArticleMolecular biology reports2025
Probiotic intervention alters immune gene expression and tumor characteristics in experimental breast cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Gut-Adipose-Tumor Axis in Obesity-Related Cancer.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a prevalent malignancy in women worldwide, with recurrence and treatment-related side effects posing significant challenges. Immunotherapy has shown promise, yet an immunosuppressive tumor microenvironment can hinder its effectiveness. Emerging evidence suggests that probiotics, particularly Lactobacillus species, may positively influence immune responses and tumor progression in the context of cancer therapy.
methodsThis study evaluated the effects of Lactobacillus reuteri PTCC1058 on tumor development and immune responses in a mouse model of breast cancer induced by 4T1 mouse breast carcinoma cells. Female BALB/c mice were divided into probiotic and control groups, receiving oral supplementation of the probiotic or PBS, respectively, for 30 days before and after tumor induction. Tumor volume and survival were assessed over 70 days. The expression levels of key immune mediators, tumor Necrosis Factor alpha (TNF alpha), Interleukin 10 (IL-10), transforming growth factor beta (TGF-β), Indoleamine 2,3-dioxygenase (IDO), and Fas ligand (FasL) were measured using quantitative real-time PCR, and histopathological analysis was conducted on tumor tissues.
resultsProbiotic treatment exhibited a trend towards reduced tumor volume and improved survival, although not statistically significant (p > 0.05). Key immune mediators showed significant changes, with TGF-β, IL-10, and IDO expressions downregulated and TNF-α and FasL upregulated in the probiotic group (P < 0.01). Histopathological analysis revealed reduced pleomorphism, mitotic activity, and focal necrosis in the probiotic group.
conclusionThe findings indicate that L. reuteri PTCC1058 may modulate the tumor microenvironment and influence immune responses in breast cancer. While further research is necessary to validate these results, probiotics could represent a complementary therapeutic strategy in breast cancer treatment.
Indexed as
Identifiers
40779195What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.